Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid used for its potent anti-inflammatory and immunosuppressive effects. It acts by binding to the glucocorticoid receptor, inhibiting phospholipase A2 activity, and suppressing the formation of pro-inflammatory mediators such as prostaglandins and leukotrienes. This results in reduced inflammation, immune response modulation, and relief from symptoms associated with various allergic, inflammatory, autoimmune, and rheumatic conditions. Shincort is typically administered via intramuscular or intra-articular injection for indications including rheumatoid arthritis (RA), synovitis, allergic rhinitis, asthma, allergic dermatitis, pemphigus vulgaris, bursitis, and certain ophthalmic diseases[3][5]. The drug is not intended for intravenous use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shincort.